Everest Medicines Ltd (1952) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Everest Medicines Ltd HK$6.13, price HK$28.70, upside -78.6%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Everest Medicines Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range HK$6.16 – HK$77.55 · fair‑value band HK$4.05 – HK$7.67 · the HK$28.70 price screens above the HK$6.13 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Everest Medicines in your weekly email
Every Wednesday you see whether Everest Medicines is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
Show more
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. The company was incorporated in 2017 and is based in Shanghai, China.
Stock analysis
Everest Medicines Ltd (1952) currently trades at HK$28.70, while our model-based Fair Value estimate is HK$6.13, implying the stock looks roughly 368.2% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: HK$4.05 (bear) to HK$7.67 (bull), the price of HK$28.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Everest Medicines Ltd reported revenue of 1.7B CNY in FY2025 versus 54.0K CNY in FY2021, a compound +1,233.3%/yr. Reported net income was −298M CNY in FY2025.
Key figures
Market cap HK$9.7B (≈ $1.2B) · P/S ratio 5.27 · EPS (TTM) HK$−0.7700 · Net margin −17.4% · Return on equity −6.4% · Return on assets (EBIT) −12.7% · Operating margin −5.3% · Revenue (TTM) HK$1.7B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 63% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −79%, 1952 screens richer than that median.
Fair Value models
Bear HK$4.05Fair Value HK$6.13Bull HK$7.67
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.32/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+141.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+411.0%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,900,614.8% (2021) → −22.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 648 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Above median
Fair Value upside−79% · Bottom 25%
Profitability
Return on assets−4% · Above median
Net margin (TTM)−17% · Below median
Operating margin (TTM)−5% · Below median
Growth and dividend
Revenue growth211% · Top 25%
Balance sheet
Debt / equity0.15× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.23× · Cheapest 25%
P/S (TTM)0.72× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)93· sector 96
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Everest Medicines Ltd (1952) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$6.13 versus a price of HK$28.70, about −79% upside (overvalued).
What is the fair value of 1952?
Our model-based fair value for Everest Medicines Ltd is HK$6.13 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$28.70.
What is the quality score of 1952?
Everest Medicines Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Everest Medicines Ltd (1952)?
Our model-based price target is the fair value of HK$6.13 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario HK$4.05, optimistic scenario HK$7.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Everest Medicines Ltd stock forecast for 2026?
Our models put fair value at HK$6.13, about −79% upside versus a price of HK$28.70 (overvalued). Cautious scenario HK$4.05, optimistic scenario HK$7.67. The calculation is refreshed regularly with new filings.
What is the revenue of Everest Medicines Ltd (1952)?
Everest Medicines Ltd reported trailing-twelve-month revenue of about HK$1.7B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Everest Medicines Ltd (1952)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Everest Medicines Ltd it is HK$6.13 per share (as of Sep 24, 2026), against a price of HK$28.70. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Everest Medicines Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1952 trades above its calculated fair value: price HK$28.70, fair value HK$6.13, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1952?
No. The price is what the market pays today (HK$28.70); the fair value is what the company's own numbers justify (HK$6.13). For Everest Medicines Ltd the two are HK$22.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Everest Medicines Ltd worth?
The market values Everest Medicines Ltd at about HK$9.7B (market capitalisation, as of Sep 24, 2026). Per share that is HK$28.70; our models calculate a fair value of HK$6.13 per share.
What do the bullish and bearish scenarios say about 1952?
Our models span a range for Everest Medicines Ltd: cautious scenario HK$4.05, base HK$6.13, optimistic HK$7.67 per share (as of Sep 24, 2026, price HK$28.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Everest Medicines Ltd (1952)?
Balance-sheet figures for Everest Medicines Ltd (as of Sep 24, 2026): return on equity −6.4%, debt of 0.15 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 1952 from its 52-week high?
Everest Medicines Ltd trades at HK$28.70, about 63% below its 52-week high of HK$77.55 and 26% above the low of HK$22.70 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$6.13 is for.
Which stocks are comparable to Everest Medicines Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Everest Medicines Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$28.70, calculated fair value HK$6.13 (−79%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1952 calculated?
We run Everest Medicines Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$6.13, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Everest Medicines Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Everest Medicines Ltd (1952)?
The closing price on Sep 22, 2026 was HK$28.70. Our model-based fair value is HK$6.13, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Everest Medicines Ltd right now?
The price sits above even our optimistic bull case (HK$7.67). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$4.05 to HK$7.67) leaves room in how you read the outcome.
Key figures of Everest Medicines Ltd
How large is the market capitalisation of Everest Medicines Ltd (1952)?
The market capitalisation of Everest Medicines Ltd is HK$9.7B (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Everest Medicines Ltd (1952)?
The price-to-sales ratio of Everest Medicines Ltd is 5.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Everest Medicines Ltd (1952)?
Earnings per share at Everest Medicines Ltd are HK$−0.7700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Everest Medicines Ltd (1952)?
The net margin of Everest Medicines Ltd is −17.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Everest Medicines Ltd (1952)?
The return on equity (ROE) of Everest Medicines Ltd is −6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Everest Medicines Ltd (1952)?
On an EBIT basis the return on assets of Everest Medicines Ltd is −12.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Everest Medicines Ltd (1952)?
The operating margin of Everest Medicines Ltd is −5.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Everest Medicines Ltd (1952)?
Revenue at Everest Medicines Ltd is growing +211% versus a year earlier (3y avg +411%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Everest Medicines Ltd (1952) generate?
The free cash flow of Everest Medicines Ltd is −HK$172M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Everest Medicines Ltd (1952) hold?
Everest Medicines Ltd holds more cash than debt, HK$1.8B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Everest Medicines Ltd in the live analysis
One click puts Everest Medicines Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
